🤔🤔What happens with #Lpa levels in #FH individuals and the related #ASCVD risk??
👍We might have a clue from #EAS #FH SC registry!
We ve just presented our unpublished results during the #SaaG sessions in #EAS CONGRESS2023!
Prof Kausik Ray EAS Society EAS Congress #EAS CONGRESS

My new book is out. I hope you will take a look and be blessed in reading it. To God be the glory, great things He has done!

Raul Santos and 5 actionable solutions to address cholesterl-related ASCVD risk #EASCongress2023

Back to back superb lectures on triglycerides and the need to lower residual risk with EPA only, omega 3. Time to start using Vazkepa in all our high risk cardiometabolic patients in addition to those with ASCVD

Vitaly Stakhov 🚢 For people my age higher total cholesterol is associated with lower mortality than a lower one. See hazard ratios below.
Look into the statistics on people who die with ascvd, if your claim is true there should be significantly more people with high ldl in this group.…

Prof. Valentin Fuster providing a look into the future of #ASCVD screening & treatment. A wonderful lecture on imaging 📸 & genomics 🧬 = imagenomics.
How do we keep a population from developing CV disease?

Incredible lecture Westchester Medical Center Westchester Medical Center Cardiology Fellowship Mount Sinai Heart

Following the previous presentation, Prof Kausik Ray shows results of a simulation aimed ar estimating the potential benefits of a 1-year (2 doses) inclisiran maintenance dose in terms of ASCVD shift to a population (500 thousand individuals) similar to those from Orion studies 👇🏽

A brief summary of the key points from Sek Kathiresan MD's presentation today here at #EASCongress2023 . Suppose LDLc could be lowered from 130 mg/dl to 40 mg/dl over a person's lifetime. He/she might never develop ASCVD. Does current chronic care model come even close to this goal? NO!👇🏽

Folks need to get real - Regarding al, the nonsensical statin hysteria that keeps popping up. As an internist with 37 years of private practice on my resume, I sadly signed many death certificates with ASCVD on line 1 yet never once signed a certificate with STATIN ADVERSITY on…

Contextualizing/adapting #PRS reporting standards for Atherosclerotic Cardiovascular Disease (ASCVD): a review by Johanna Smith

Why Does the Current Primary #Prevention Approach Not Work in #Young_Adults ?
Since most #ASCVD events occur at older ages, age is a dominant contributor in all #risk_estimating equations leading to very low short-term risk in the population. BCM_CVRI BCM Cardiology BCM Department of Medicine

🎨 #Art and #Architecture 🕌

youtu.be/ZOm7hAaMaY4

How to eliminate the #1 cause of death, ASCVD ('heart disease'), from your life:

1. Quit smoking.
2. Maintain blood pressure close to 120/80.
3. Lower your LDL levels, that's the 'bad' cholesterol.

Address these factors, and the leading serial killer will lose its top spot.

Excited to share this review with you all 😊
pubmed.ncbi.nlm.nih.gov/37223852/
#ASCVD #PRS

'Alirocumab ➕ high-intensity statin therapy resulted in significant regression of coronary plaque burden and plaque stabilization on coronary computed tomographic angiography over 78 weeks in these groups of patients with familial hypercholesterolemia without clinical ASCVD'

Healthy childhood for a healthy future - 'Lipid profile screening in children and ASCVD prevention’

#Center for Psycho-Social and Medical Research, Prishtina, Kosovo! ❤️

GLP1-RA and ASCVD
#EASCongress2023

'OxPLs are able to boost inflammation by inducing a “hypermetabolic” state in phagocytes that amplifies the production of IL-1β ' ' Lp(a) is pro-inflammatory already in young healthy individuals without confounding effects of existing ASCVD'.

Was texted this ECG. ED consult for new chest pain. Early 40’s male. No reported ASCVD risk factors. Troponin I pending. #CardioTwitter #Cardiology #FOAMed #MedTwitter

There are movies and then there are great movies. See the experts' list of the best in the history of film

One word to describe #EASCongress2023 : Refreshing. I really enjoyed talks/sessions (and there were many) highlighting the role of multiple players in ASCVD including NAFLD, diabetes, stress, dementia.. Kudos to the Scientific Programme Committee! 👏

William Cromwell, MD Phillip Albertson LipoFan Dr Cromwell, the authors in your ref's you say ⬆️plasma ApoB = ⬆️'likelihood' of subendothelial retention. Fair. But concentration gradient-ASCVD correlation at pop. level doesn't explain variability in ApoB➡️ASCVD in individuals. From Jan Boren:

CAC scores are associated with ASCVD risk equivalent to stable secondary prevention populations --> important for guiding the intensity of preventive approaches more broadly.
From @jaccjournals jacc.org/doi/10.1016/j.…
Julia Grapsa Henry Han , MBBS, MD Leslee Shaw